Posted on 11/20/18
Cambrex To Acquire Avista Pharma Solutions For $252M
Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms
Posted on 11/20/18
Is Johnson & Johnson A Buy Here?
Summary Johnson & Johnson is a Dividend King that recently raised their dividend for the 56th consecutive year. Packed with a well diversified portfolio, JNJ can . . .
Posted on 11/19/18
Better Buy: Celgene Corporation vs. Merck & Co.
Two drug stocks diverged in a yellow wood. And sorry I could not buy both and be one investor, long I stood.My apologies to Robert Frost . . .
Posted on 11/19/18
Where Will Pfizer Inc. Be in 5 Years?
With a little momentum at the end of 2018, Pfizer Inc. (NYSE:PFE) could be headed for its best year yet in the 21st century. The big . . .
Posted on 11/19/18
Better Buy: Abbott Laboratories vs. Johnson & Johnson
When you think about blue chip stocks in healthcare, which stocks come to mind? For many, Abbott Laboratories (NYSE:ABT) and Johnson & Johnson (NYSE:JNJ) would be . . .
Posted on 11/19/18
Cantel Medical To Acquire Omnia For Europe Expansion
Cantel Medical (CMD) announced it has agreed to acquire Omnia for $31.9 million.
Posted on 11/19/18
Why Teva Pharmaceutical Is Up 20% in 2018 So Far
Teva Pharmaceutical Industries (NYSE:TEVA) borrowed a large amount of money to become the leading manufacturer of generic drugs -- just before the market for generic drugs . . .
Posted on 11/19/18
Aquestive Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration
Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in regards to its . . .
Posted on 11/16/18
J&J Snack Foods Has To Pull Back, Right?
Summary JJSF has risen nicely since the recession, buoyed by ever-expanding multiples. The market even shrugged at a disappointing Q4 that capped off a rather weak . . .
Posted on 11/16/18
Why Johnson & Johnson's Up 3% So Far in 2018
The healthcare industry has done extremely well in 2018, and many companies in the space have posted stellar gains. That makes the lackluster gains that industry . . .
Posted on 11/16/18
Why Pfizer Is Up 19% in 2018 So Far
It's been a banner year for shares of America's largest pharmaceutical company, but you wouldn't know it by looking at Pfizer's (NYSE:PFE) top line in recent . . .
Posted on 11/15/18
Helius Medical Technologies Announces Pricing of Public Offering of Class A Common Stock
NEWTOWN, Pa., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) announced the pricing of an underwritten public offering of 2,121,212 shares of . . .
Posted on 11/15/18
Exalenz Announces Third Quarter 2018 Financial Results
MODI’IN, Israel and MANASQUAN, N.J., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for . . .
Posted on 11/14/18
SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended September 30, . . .
Posted on 11/14/18
Health Plans Project 2019 Premiums to Increase by 5.2% for Group Fully-Insured Plans and 4.4% for Individual Plans
PHILADELPHIA--(BUSINESS WIRE)--Health plans are expecting 2019 premium rates to increase by 5.2% for Group fully-insured plans, while growing by 4.4% for Individual plans. For Group plans, . . .
Posted on 11/13/18
ImmunoRestoration Announces IND Transfer Completed
DOYLESTOWN, Pa.--(BUSINESS WIRE)--ImmunoRestoration, Inc., a biotech recently formed to lead the development and commercialization of a novel immunotherapeutic cancer cell therapy platform, announces the receipt of . . .
Posted on 11/13/18
Ferring Pharmaceuticals Enters Exclusive Agreement with INVO Bioscience
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today that it has signed an agreement to acquire from INVO Bioscience Inc. (OTCQB:IVOB) the exclusive U.S. commercialization rights for the . . .
Posted on 11/13/18
Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018
NEWTOWN, Pa., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small . . .
Posted on 11/13/18
J&J Snack Foods Corp (JJSF) Q3 2018 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.J&J Snack Foods Corp (NASDAQ:JJSF)Q3 2018 Earnings Conference CallNov. 09, 2018, 10:00 a.m. ETContents: Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorWelcome to the . . .
Posted on 11/13/18
Why Celgene's Stock Nosedived in October
What happenedShares of the blue-chip biotech giant Celgene Corp. (NASDAQ:CELG) sank by a worrisome 20.3% in October, according to S&P Global Market Intelligence. The good news, . . .
Posted on 11/13/18
Amneal Completes Transition Agreement With Lannett Company
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal will take . . .
Posted on 11/13/18
Aetna Medicare HMO Plans in Pennsylvania Awarded High-Quality Rating
HARTFORD, Conn.--(BUSINESS WIRE)--Aetna’s (NYSE: AET) Medicare Advantage Prescription Drug (MAPD) HMO plan serving the state of Pennsylvania has been awarded 4.5 stars out of 5 by . . .
Posted on 11/9/18
Soligenix Announces Recent Accomplishments And Third Quarter 2018 Financial Results
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced . . .
Posted on 11/9/18
Here's Why Celldex Therapeutics, Inc. Surged on Thursday
What happenedShares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), a clinical-stage biotech developing novel new cancer therapies, rose 11.8% following the company's third-quarter earnings report on Thursday. Progress . . .
Posted on 11/8/18
Cambrex Reports Third Quarter 2018 Financial Results
EAST RUTHERFORD, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, and . . .

